Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 7

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 7
---
 expenses, to pay a non-accountable      
 expense allowance up to 1.0% of the aggregate gross proceeds raised in this offering, and to sell to the placement agent warrants, or       
 the Placement Agent Warrants, to purchase up to a number of Depositary Shares equal to 5.0% of the aggregate number of Units and Pre-Funded 
 Units being offered hereby. The Placement Agent Warrants and the Depositary Shares issuable upon exercise of the Placement Agent Warrants   
 are also being registered under the registration statement of which this prospectus forms a part. We refer you to “Plan of Distribution”    
 for additional information regarding placement agent compensation.                                                                          |

We are a “foreign private issuer,” as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions under Section 16 of the Exchange Act. Moreover, we are not required to file periodic reports and financial statements with the Securities and Exchange Commission as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.

As a foreign private issuer, we have elected to follow home country practice instead of complying with NASDAQ Listing Rule 5635(d) shareholder approval requirements, we are not required to obtain, and do not intend to seek, shareholder approval of the issuance of the Units, to the extent that such approval would otherwise be required for a domestic issuer.

Investing in our securities involves risks. See “Risk Factors” beginning on page 14 of this prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>Sole Placement Agent

Maxim Group LLC

The date of this prospectus is
, 2025</div>

<div align='center'>TABLE OF CONTENTS</div>

|                                                         | Page |
| ABOUT THIS PROSPECTUS                                   |    1 |
| PRESENTATION OF FINANCIAL AND OTHER INFORMATION         |    2 |
| PROSPECTUS SUMMARY                                      |    5 |
| RISK FACTORS                                            |